share_log

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27

HC Wainwright & Co.維持對Viridian Therapeutics的買入,將目標股價下調至27美元
Benzinga ·  05/09 15:03

HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $37 to $27.

HC Wainwright & Co. 分析師道格拉斯·曹維持Viridian Therapeutics(納斯達克股票代碼:VRDN)的買入並將目標股價從37美元下調至27美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論